BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 31710020)

  • 1. Comprehensive Study of Surgical Treated Lung Adenocarcinoma with Ground Glass Nodule Component.
    Xu Y; Zheng M; Wang N; Wang R
    Med Sci Monit; 2019 Nov; 25():8492-8498. PubMed ID: 31710020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma.
    Takamochi K; Oh S; Matsunaga T; Suzuki K
    J Thorac Cardiovasc Surg; 2017 Nov; 154(5):1768-1774.e1. PubMed ID: 28826599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging Features Suggestive of Multiple Primary Lung Adenocarcinomas.
    Zhang Y; Li G; Li Y; Liu Q; Yu Y; Ma Y; Pan Y; Zhang Y; Hu H; Sun Y; Zhang Y; Xiang J; Chen H
    Ann Surg Oncol; 2020 Jun; 27(6):2061-2070. PubMed ID: 31863415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matched-pair analysis of a multi-institutional cohort reveals that epidermal growth factor receptor mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma.
    Matsumura Y; Suzuki H; Ohira T; Shiono S; Abe J; Sagawa M; Sakurada A; Katahira M; Machida Y; Takahashi S; Okada Y
    Lung Cancer; 2017 Dec; 114():23-30. PubMed ID: 29173761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased risk of recurrence in resected EGFR-positive pN0M0 invasive lung adenocarcinoma.
    Ito M; Miyata Y; Kushitani K; Yoshiya T; Kai Y; Tsutani Y; Mimura T; Konishi K; Takeshima Y; Okada M
    Thorac Cancer; 2018 Dec; 9(12):1594-1602. PubMed ID: 30298562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis.
    Ito M; Miyata Y; Tsutani Y; Ito H; Nakayama H; Imai K; Ikeda N; Okada M
    Lung Cancer; 2020 Mar; 141():107-113. PubMed ID: 32035371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal Growth Factor Receptor Mutation as a Risk Factor for Recurrence in Lung Adenocarcinoma.
    Hayasaka K; Shiono S; Matsumura Y; Yanagawa N; Suzuki H; Abe J; Sagawa M; Sakurada A; Katahira M; Takahashi S; Endoh M; Okada Y
    Ann Thorac Surg; 2018 Jun; 105(6):1648-1654. PubMed ID: 29486179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk Factors of Recurrence in Patients With Clinical Stage IA Adenocarcinoma Presented as Ground-Glass Nodule.
    Su H; Dai C; Xie H; Ren Y; She Y; Kadeer X; Xie D; Zheng H; Jiang G; Chen C
    Clin Lung Cancer; 2018 Sep; 19(5):e609-e617. PubMed ID: 29803575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pan-Driver-Negatives versus Epidermal Growth Factor Receptor Mutants for C-Stage IA Lung Adenocarcinoma with Ground-Glass Opacity.
    Li M; Xi J; Zhang H; Jin X; Zhang J; Feng M; Zhan C; Wang Q
    Ann Thorac Cardiovasc Surg; 2022 Oct; 28(5):320-328. PubMed ID: 35644565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic implications of EGFR mutation and ALK rearrangement for the long-term outcomes of patients with resected lung adenocarcinomas.
    Kim H; Lee HJ; Hong H; Kim YJ; Kim KG; Jeon YK; Kim YT
    Thorac Cancer; 2019 Jul; 10(7):1619-1627. PubMed ID: 31215177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis of epidermal growth factor receptor-mutated stage I lung adenocarcinoma with radiologically solid features.
    Hattori A; Matsunaga T; Fukui M; Takamochi K; Suzuki K
    Eur J Cardiothorac Surg; 2022 Mar; 61(4):769-777. PubMed ID: 34791156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR and TTF-1 gene amplification in surgically resected lung adenocarcinomas: clinicopathologic significance and effect on response to EGFR-tyrosine kinase inhibitors in recurred cases.
    Lee JS; Kim HR; Lee CY; Shin M; Shim HS
    Ann Surg Oncol; 2013 Sep; 20(9):3015-22. PubMed ID: 23525704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment.
    Chung KP; Huang YT; Chang YL; Yu CJ; Yang CH; Chang YC; Shih JY; Yang PC
    Chest; 2012 Feb; 141(2):420-428. PubMed ID: 21799026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
    Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status.
    Isaka T; Ito H; Yokose T; Saito H; Adachi H; Murakami K; Miura J; Kikunishi N; Rino Y
    BMC Cancer; 2022 Sep; 22(1):966. PubMed ID: 36085020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Prognostic Value of Vascular Invasion in Resected Lung Adenocarcinomas According to Epidermal Growth Factor Receptor Mutational Status.
    Lee KH; Chung JH; Cho S; Lee JS; Kim H
    Clin Lung Cancer; 2023 Nov; 24(7):e291-e299.e1. PubMed ID: 37479587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Utility of Thyroid Transcription Factor 1 (TTF-1), Napsin A, Excision Repair Cross-Complementing 1 (ERCC1), Anaplastic Lymphoma Kinase (ALK) and the Epidermal Growth Factor Receptor (EGFR) Expression in Small Biopsy in Prognosis of Patients with Lung Adenocarcinoma - A Retrograde Single-Center Study from Croatia.
    Piljić Burazer M; Mladinov S; Ćapkun V; Kuret S; Glavina Durdov M
    Med Sci Monit; 2017 Jan; 23():489-497. PubMed ID: 28128193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas.
    Guerrera F; Renaud S; Tabbó F; Voegeli' AC; Filosso PL; Legrain M; Boita M; Schaeffer M; Beau-Faller M; Ruffini E; Falcoz PE; Inghirami G; Oliaro A; Massard G
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):680-688. PubMed ID: 28329143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncologic outcomes of segmentectomy compared with lobectomy for clinical stage IA lung adenocarcinoma: propensity score-matched analysis in a multicenter study.
    Tsutani Y; Miyata Y; Nakayama H; Okumura S; Adachi S; Yoshimura M; Okada M
    J Thorac Cardiovasc Surg; 2013 Aug; 146(2):358-64. PubMed ID: 23477694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of epidermal growth factor receptor mutation and the presence of high-grade patterns is associated with recurrence in resected stage I lung adenocarcinoma.
    Kondo Y; Ichinose J; Ninomiya H; Hashimoto K; Matsuura Y; Nakao M; Ishikawa Y; Okumura S; Satoh Y; Mun M
    Interact Cardiovasc Thorac Surg; 2022 Jul; 35(2):. PubMed ID: 35266536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.